Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica

L. Pulsatelli, R. Meliconi, L. Boiardi, P. Macchioni, C. Salvarani, A. Facchini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Evaluation of serum concentrations of chemotactic cytokines (chemokines) in patients with polymyalgia rheumatica at disease diagnosis and during a six-month period of corticosteroid treatment. Methods: Sera were obtained from patients at the time of PMR diagnosis and subsequently after one week, two weeks, one month, three months and six months. At each time point a clinical and laboratory evaluation was performed. Serum concentrations of IL-8, GROα, RANTES, MCP-1, and MIP1α were evaluated by commercial ELISA kits. Results: Only RANTES serum levels were significantly higher in PMR patients than in controls. No correlation was found between RANTES concentrations and laboratory and clinical features. Chemokine levels reached their lowest level after one month of steroid treatment and remained in the normal range thereafter. Conclusions: The production of RANTES is enhanced in untreated PMR patients; corticosteroid treatment results in a normalization of chemokine levels.

Original languageEnglish
Pages (from-to)263-268
Number of pages6
JournalClinical and Experimental Rheumatology
Volume16
Issue number3
Publication statusPublished - 1998

Fingerprint

Polymyalgia Rheumatica
Chemokine CCL5
Chemokines
Serum
Adrenal Cortex Hormones
Interleukin-8
Reference Values
Therapeutics
Enzyme-Linked Immunosorbent Assay
Steroids

Keywords

  • Corticosteroid treatment
  • Polymyalgia rheumatica
  • RANTES

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. / Pulsatelli, L.; Meliconi, R.; Boiardi, L.; Macchioni, P.; Salvarani, C.; Facchini, A.

In: Clinical and Experimental Rheumatology, Vol. 16, No. 3, 1998, p. 263-268.

Research output: Contribution to journalArticle

@article{f4593bd32f0a436d8c8306e75a4f7bdc,
title = "Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica",
abstract = "Objective: Evaluation of serum concentrations of chemotactic cytokines (chemokines) in patients with polymyalgia rheumatica at disease diagnosis and during a six-month period of corticosteroid treatment. Methods: Sera were obtained from patients at the time of PMR diagnosis and subsequently after one week, two weeks, one month, three months and six months. At each time point a clinical and laboratory evaluation was performed. Serum concentrations of IL-8, GROα, RANTES, MCP-1, and MIP1α were evaluated by commercial ELISA kits. Results: Only RANTES serum levels were significantly higher in PMR patients than in controls. No correlation was found between RANTES concentrations and laboratory and clinical features. Chemokine levels reached their lowest level after one month of steroid treatment and remained in the normal range thereafter. Conclusions: The production of RANTES is enhanced in untreated PMR patients; corticosteroid treatment results in a normalization of chemokine levels.",
keywords = "Corticosteroid treatment, Polymyalgia rheumatica, RANTES",
author = "L. Pulsatelli and R. Meliconi and L. Boiardi and P. Macchioni and C. Salvarani and A. Facchini",
year = "1998",
language = "English",
volume = "16",
pages = "263--268",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica

AU - Pulsatelli, L.

AU - Meliconi, R.

AU - Boiardi, L.

AU - Macchioni, P.

AU - Salvarani, C.

AU - Facchini, A.

PY - 1998

Y1 - 1998

N2 - Objective: Evaluation of serum concentrations of chemotactic cytokines (chemokines) in patients with polymyalgia rheumatica at disease diagnosis and during a six-month period of corticosteroid treatment. Methods: Sera were obtained from patients at the time of PMR diagnosis and subsequently after one week, two weeks, one month, three months and six months. At each time point a clinical and laboratory evaluation was performed. Serum concentrations of IL-8, GROα, RANTES, MCP-1, and MIP1α were evaluated by commercial ELISA kits. Results: Only RANTES serum levels were significantly higher in PMR patients than in controls. No correlation was found between RANTES concentrations and laboratory and clinical features. Chemokine levels reached their lowest level after one month of steroid treatment and remained in the normal range thereafter. Conclusions: The production of RANTES is enhanced in untreated PMR patients; corticosteroid treatment results in a normalization of chemokine levels.

AB - Objective: Evaluation of serum concentrations of chemotactic cytokines (chemokines) in patients with polymyalgia rheumatica at disease diagnosis and during a six-month period of corticosteroid treatment. Methods: Sera were obtained from patients at the time of PMR diagnosis and subsequently after one week, two weeks, one month, three months and six months. At each time point a clinical and laboratory evaluation was performed. Serum concentrations of IL-8, GROα, RANTES, MCP-1, and MIP1α were evaluated by commercial ELISA kits. Results: Only RANTES serum levels were significantly higher in PMR patients than in controls. No correlation was found between RANTES concentrations and laboratory and clinical features. Chemokine levels reached their lowest level after one month of steroid treatment and remained in the normal range thereafter. Conclusions: The production of RANTES is enhanced in untreated PMR patients; corticosteroid treatment results in a normalization of chemokine levels.

KW - Corticosteroid treatment

KW - Polymyalgia rheumatica

KW - RANTES

UR - http://www.scopus.com/inward/record.url?scp=0031972205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031972205&partnerID=8YFLogxK

M3 - Article

C2 - 9631747

AN - SCOPUS:0031972205

VL - 16

SP - 263

EP - 268

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -